174 results about "Antigen binding site" patented technology

The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies.

The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 “v-regions”, which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 “v-regions” can be used on each polypeptide chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Humanized antibody molecules (HAMs) are described having specificity for human milk fat globule and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody CTMO1 and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.

The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention provides a novel artificially-designed triabody comprising three polypeptide chains. A first polypeptide chain comprises a first heavy-chain variable domain, and a second polypeptide chain comprises a first light-chain variable domain, and the first heavy-chain variable domain pairs with the first light-chain variable domain to form a first antigen binding site; and a third polypeptide chain comprises a single-domain second antigen binding site and a single-domain third antigen binding site. The present invention also provides polynucleotide encoding the triabody, a vector comprising the polynucleotide, host cells comprising the polynucleotide or the vector, immunoconjugate comprising the triabody, a pharmaceutical composition comprising the triabody or the immunoconjugate, and applications of the triabody in immunotherapy, prevention and / or diagnosis of diseases.

A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

The invention belongs to the technical field of biosensors, and specifically discloses a jettisonable one-step electro-deposition immune-biosensor for detecting histamine and a preparation method of the immune-biosensor. The immune-biosensor adopts an electrode coated with a prussian blue, chitosan and nanogold composite film, wherein histamine coating antigen is fixed on the electrode, the molar concentration ratio of nanogold to prussian blue in the composite film is 1:2000 to 1:20, and the massic volume content of chitosan is 0.01-0.05%. Furthermore, the composite film is formed on the surface of the electrode through a one-step electrode deposition manner, the deposition step is simpler than a preparation step of the conventional electrode modified by high-molecular polymer, and the antigen binding site can be easily exposed out. According to the electro-deposition immune-biosensor, competition immunoreaction and a biosensor are combined, and a series of property characteristics such as a histamine detection working curve can be obtained according to needs, and the jettisonable one-step electro-deposition immune-biosensor has the advantages of simplicity in operation, high sensitivity, rapidness, convenience and the like, and can be used for on-site rapid detection for histamine in a sample.

The invention provides a leukemia bacteriophage single-chain antibody library, which uses phasmid pCANTA-5E as a carrier, has storage capacity of 1.5*10<9>, and has excellent diversity in proving of DNA (deoxyribonucleic acid) sequencing. A leukemia cell specific completely humanized single-chain antibody can be obtained conveniently in multiple screenings by using a specific leukemia related antigen as a target through a bacteriophage representation technology from the completely humanized single-chain antibody library. The antibody library provided by the invention has high storage capacity and excellent diversity, and comprises a combination of complete humanized single-chain antibodies; and a single-chain antibody is formed by connection of a heavy chain variable region VH and a light chain variable region VL through a connecting peptide (GGGGS)3, and contains a complete antigen-binding site. The method has the advantages of strong operability and high storage capacity, and can be used for conveniently screening the leukemia cell specific completely humanized single-chain antibody; and the completely humanized single-chain antibody can be used for preparing a target medicament, which is used for treating leukemia.

A medical device coated with carrier macromolecules, wherein the carrier macromolecules are conjugated with a therapeutic agent. The carrier macromolecules may be antibodies which bind the therapeutic agent at the antigen binding site or by covalent bonding. The carrier macromolecules may be tethered to the surface of or dispersed within a coating on the medical device. The carrier macromolecules may release the therapeutic agent upon exposure to a trigger, which may be exposure to an aqueous environment, or a change in the pH or the ionic strength of the environment. The carrier macromolecules may also be bispecific antibodies directed to both a therapeutic agent and a target antigen. In some cases, binding of the target antigen causes the therapeutic agent to be released from the bispecific antibody. Also provided are methods of controlling the release and targeting of therapeutic agents eluted from a medical device.

The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1:FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to use of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X7 receptors expressed by live cells.

The present invention provides a novel artificially designed antibody molecule, which comprises (i) a single domain antigen binding site; (ii) an antigen binding Fab fragment; wherein (i) is located at the N-terminus of a light chain variable domain (VL) of (ii) or the C-terminus of a light-chain constant region (CL), or the (i) is located at the N-terminus of a heavy chain variable domain (VH) ofthe (ii) or the C-terminus of an immunoglobulin CH1 domain, (i) and (ii) respectively bind the same or different antigens, and a linking peptide is existed or does not exist in between (i) and (ii),and an (iii) immunoglobulin Fc domain is positioned at the C-terminus of (i) and (ii). The invention also provides the use of the polynucleotide encoding the antibody molecule, a vector comprising thepolynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate comprising the antibody molecule, and a pharmaceutical composition, and the antibody molecule for immunotherapy, prevention and / or diagnosis of a disease.

The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

The invention belongs to the technical field of immunological detection, mainly relates to immunological quantitative determination of pollution of heavy metal cadmium ion in water, and more specifically relates to a method for detecting cadmium ion pollution in water by a blocking ELISA (Enzyme-Linked Immunosorbent Assay) method. The method is characterized in that Cd<2+> and excessive EDTA are chelated to form a Cd<2+>-EDTA chelate compound; the Cd<2+>-EDTA chelate compound in water and Cd<2+>-ITCBE-OVA coated on an enzyme label plate competes an antigen-binding site of a Cd<2+>-EDTA monoclonal antibody, HRP-labeled goat anti mouse IgG and a TMB substrate are added, after coloration is terminated, A450nm value is read by an ELIASA, by contrasting with a standard curve, the Cd<2+> concentration in water can be obtained. According to the invention, the treatment method of a water sample to be detected is sample, a large-scale apparatus is not required during the detection process, the operation is simple and rapid, sample detection amount is large, timeliness is strong, detection cost is low, popularization is convenient, detection result accuracy is high, repeatability is good, and the detection range is 5.0-512mum g / L.